Portfolio BMI I

4-Antibody AG, Switzerland
Preclinical checkpoint antibody programs derived with a powerful antibody technology

Webpage: www.agenusbio.com
BMI responsible: K. Fischer
Company status: Trade sale

4-Antibody, a wholly-owned subsidiaryof Agenus Inc., is located in Basel, Switzerland and Jena, Germany. Agenus is a Nasdaq-listed company with a partnered late-stage adjuvant pipeline, vaccine candidates in clinical phase II, and checkpoint antibodies in preclinical testing derived from 4-Antibody. These antibody therapeutics focus on immuno-oncology targeting checkpoint modulators such as GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.

7TM Pharma, Denmark
Targeting novel trans-membrane receptors against obesity

Webpage: None
BMI responsible: M. Hosang
Company status: Liquidated

7TM Pharma was a Danish discovery and development company which focused on new medicines targeting 7TM receptors, and had anti-obesity compounds in early stage of clinical development.

Affimed Therapeutics AG, Germany
Discovering and developing highly targeted cancer immunotherapies

Webpage: www.affimed.com
BMI responsible: P.Burgermeister
Company status: Public

Affimed Therapeutics AG, based in Heidelberg (D), is a biopharmaceutical company focusing on the development of next generation antibodies against various indications using its proprietary antibody format technology platform. The company went public on the Nasdaq (symbol: AFMD) in September 2014.

Arpida AG, Switzerland
Clinical stage antibacterials and antifungals

Webpage: www.evolva.com
BMI responsible: T. Moeller
Company status: Exited

Arpida was a publicly quoted biopharmaceutical company that focused on the discovery and development of novel products for the treatment of bacterial infections. In December 2009, the company merged with Evolva Holding AG.

Delenex Therapeutics AG, Switzerland (now part of Cell Medica Ltd.)
Discovery and development of antibody fragments in dermatology

Webpage: cellmedica.co.uk
BMI responsible: P. Burgermeister
Company status: Private

Delenex Therapeutics was a Zurich-based clinical-stage biotechnology company focusing on research and development of antibody fragments for delivering next generation therapeutic application. The company was created as a spin-off of ESBAtech in 2009 and was acquired in July 2016 by the British company Cell Medica Ltd.

Dolthera GmbH, Germany
Nucleic acid based anti-inflammatory drugs

Webpage: None
BMI responsible: M. Hosang
Company status: Liquidated

Dolthera was a development-stage biopharmaceutical company discovering and developing a novel class of nucleic acid based anti-inflammatory drugs which were based on oligonucleotides that act as decoys for disease-related transcription factors.

ESBATech AG, Switzerland
Ophthalmic antibody fragments

Webpage: www.esbatech.com
BMI responsible: P. Burgermeister
Company status: Trade sale

ESBATech AG is a biopharmaceutical company focusing on the development of fully human single-chain antibody fragments for new therapeutic applications with high stability, affinity and production yields. It was acquired by Alcon Research Ltd. in September 2009.

EyeSense AG, Switzerland & Germany
Ophthalmic diagnostic systems

Webpage: www.eyesense.com
BMI responsible: T. Möller
Company status: Private

Eyesense is a spin-out from Ciba Vision AG, located in Grossostheim (D), which develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. They make blood glucose control easier and pain-free through innovative monitoring devices.

Glycart AG, Switzerland
Antibodies based on GlycoMAb technology

Webpage: www.roche.com
BMI responsible: M. Münchbach
Company status: Trade sale

GlycArt Biotechnlogy was a biopharmaceutical company developing a new generation of antibodies based on its proprietary GlycoMAb technology. The company was acquired in 2005 Roche for CHF 235 million. In July 2014, its lead product Gazyvaro was approved against CLL in Europe.

Lumavita AG, Switzerland
Anti-Infectious treatments for women's health

Webpage: None
BMI responsible: G. Ries
Company status: Liquidated

Lumavita AG was a privately held pharmaceutical company based in Basel focusing on infectious diseases related to women's health (incl. pentamycin for the treatment of vaginal infections)

Okairòs AG, Switzerland & Italy
Pioneering T-cell based vaccines for major infectious diseases

Webpage: www.okairos.it
BMI responsible: M. Hosang
Company status: Trade sale

Okairòs AG was a spin-off company from the IRBM in Rome (Merck Inc.) focusing on the discovery and development of genetic T-cell vaccines including hepatitis C virus (HCV). In May 2013, Okairos AG was acquired by GlaxoSmithKline for EUR 250 million.

Oncalis AG, Switzerland
Kinase inhibitors in oncology

Webpage: None
BMI responsible: G. Ries
Company status: Liquidated

Oncalis AG was a biotech company that focused on the discovery and development of small molecule kinase inhibitors for oncology indications using its proprietary yeast-cell based, high-throughput screening platform for receptor tyrosine kinases. The company was liquidated end of 2012.

Polyphor AG, Switzerland
Discovery and development of macrocycle drugs

Webpage: www.polyphor.com
BMI responsible: T. Möller
Company status: Private

Polyphor AG, headquartered in Allschwil (CH), is a biotech company developing focused small molecule libraries for lead optimization and novel compound classes Protein Epitope Mimetics (PEM) which combine elements of protein and classical small molecules.

Santhera Pharmaceuticals Holding AG, Switzerland
Treating mitochondrial and neuromuscular diseases

Webpage: www.santhera.com
BMI responsible: T. Möller
Company status: Exited

Santhera Pharmaceuticals is a publicly quoted biotech company that focuses on the development of small molecule drugs for treating neuromuscular and neurodegenerative diseases.

Spinal Cord Therapeutics GmbH, Germany
Treatments for spinal cord injury

Webpage: None
BMI responsible: M. Hosang
Company status: Liquidated

Spinal Cord Therapeutics GmbH (formerly Neuraxo GmbH) developed treatments for spinal cord injury.

Spinelab AG, Switzerland
Dynamic spine stabilization

Webpage: None
BMI responsible: T. Möller
Company status: Liquidated

Spinelab AG is a medical technology company focusing on dynamic spine stabilization devices with the aim to preserve some level of motion, facilitate load/stress sharing, provide stability and maintain sagittal alignment.

SuppreMol GmbH, Germany
Delivering novel therapeutics for the treatment of autoimmune diseases

Webpage: www.suppremol.com
BMI responsible: M. Hosang
Company status: Trade sale

SuppreMol GmbH is a privately held biopharmaceutical company based in Munich (D), developing and manufacturing novel immunomodulatory molecules for the treatment of autoimmune diseases.

Symetis SA, Switzerland
Minimally-invasive transcatheter heart valve implants

Webpage: www.symetis.com
BMI responsible: T. Möller
Company status: Private

Symetis SA is a leader in minimally-invasive transcatheter heart valve implantation devices to treat valvular heart disease. The company has safe and intuitive aortic heart valve replacement systems that alleviate the burden of disease of high-risk patients suffering from severe aortic stenosis. Their devices give physicians greater control during delicate surgical interventions and result in superb patient outcomes.

Thommen Medical AG, Switzerland
Development, production and distribution of dental implants

Webpage:www.thommen-medical.com
BMI responsible: T. Möller
Company status: Buy-out

Thommen Medical is an oral implant company dedicated to develop, manufacture and market a new dental implant system. In 2007, Thommen Medical announced that two groups of private investors have acquired the majority of the company from venture capital investors.

Vivendy Therapeutics AG, Switzerland
Enzyme replacement therapy

Webpage: None
BMI responsible: G. Ries
Company status: Liquidated

Vivendy Therapeutics AG, a spin-off from Inotech Biotechnologies AG, developed an enzyme replacement therapy (ERT) for Morbus Morquio, a rare lysosomal storage disease. The company is in liquidation.

Portfolio BioMedInvest I

Footer